45 research outputs found
Comparison of referring and final pathology for patients with Tâcell lymphoma in the National Comprehensive Cancer Network
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/107537/1/cncr28676.pd
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma
CD10 down expression in follicular lymphoma correlates with gastrointestinal lesion involving the stomach and large intestine
The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma
Interleukin (IL)-31A binds to an heterodimer composed of IL-31 receptor A (IL-31RA) and Oncostatin M Receptor (OSMR). The IL-31/
IL-31R complex is involved in the pathogenesis of various skin diseases, including cutaneous T-cell lymphoma. No information is
available on the relations between the IL-31/IL-31R complex and B-cell lymphoma. Here we have addressed this issue in follicular
lymphoma (FL), a prototypic germinal center(GC)-derived B-cell malignancy. IL-31 enhanced primary FL cell proliferation through
IL-31R-driven signal transducer and activator of transcription factor 1/3 (STAT1/3), extracellular signalâregulated kinase 1/2 (ERK1/2)
and Akt phosphorylation. In contrast, GC B cells did not signal to IL-31 in spite of IL-31R expression. GC B cells expressed
predominantly the inhibitory short IL-31RA isoform, whereas FL cells expressed predominantly the long signaling isoform.
Moreover, GC B cells lacked expression of other IL-31RA isoforms potentially involved in the signaling pathway. IL-31 protein
expression was significantly higher in surface membrane than in cytosol of both FL and GC B cells. IL-31 was detected in plasma
membrane microvesicles from both cell types but not released in soluble form in culture supernatants. IL-31 and IL-31RA expression
was higher in lymph nodes from FL patients with grade IIIa compared with grade I/II, suggesting a paracrine and/or autocrine role
of IL-31/IL-31RA complex in tumor progression through microvesicle shedding
MIB-1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy
Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine.
Mantle cell lymphoma is a clinically heterogeneous disease occurring within a heterogeneous patient population, highlighting a need for personalized therapy to ensure optimal outcomes. It is therefore critical to understand the benefits and risks associated with both intensive and deintensified approaches. In the following review we provide a therapeutic roadmap to strategically guide treatment for newly diagnosed and relapsed/refractory patients highlighting pivotal and recently published results involving known and novel therapies